LONDON, UK — October 10, 2025 — Leads & Copy — Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) has provided an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The company’s proprietary centenarian SIRT6 gene therapy has now been administered for the second time in its ongoing randomized, controlled trial involving 28 beagles aged 10 years and older.
In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects observed, while control animals remained untreated. The repeat administration has again demonstrated an excellent safety and tolerability profile, marking a key milestone in the study. The dogs are in a follow-up period expected to conclude in January 2026.
With safety confirmed in repeat administration, Genflow will continue to advance its animal health initiative toward the next stage of clinical evaluation and partnership development.
Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented that the company is very encouraged by the continued safety validation of their SIRT6 therapy and by the strong engagement they’re seeing from established players in the animal health industry.
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population.
Contacts:
Genflow Biosciences
Harbor Access
Dr Eric Leire, CEO
Jonathan Paterson, Investor Relations
+32-477-495-881
+1 475 477 9401
Jonathan.Paterson@Harbor-access.com
Corporate Brokers
Capital Plus Partners Ltd
Jon Critchley, +44207 432 0501
Source: Genflow Biosciences
